Use of biologics for the treatment of moderate-to-severe asthma: the age of personalized medicine

Department

Allergy and Immunology

Document Type

Article

Publication Title

Current Opinion in Pulmonary Medicine

Abstract

PURPOSE OF REVIEW: There are multiple FDA-approved biologics to treat poorly controlled moderate-to-severe asthma. Given the heterogeneity of asthma and the lack of head-to-head data between biologics, selecting the best biologic for a patient can be difficult. This review summarizes the key literature to date, in hopes of facilitating an evidence-based approach to selecting the most appropriate biologic for patients with asthma.
RECENT FINDINGS: In addition to unique mechanisms of action, there is increasing literature on predictors of response to each biologic, such as sensitizations to aeroallergens, peripheral eosinophil count, total serum IgE, and exhaled nitric oxide. Biologics available for asthma are also being increasingly studied in comorbid conditions with asthma, and this may facilitate selecting the most appropriate biologic for a patient. In the absence of head-to-head studies, there is literature of switching between biologics whenever necessary.
SUMMARY: The authors outline an approach to selecting a biologic based on various considerations, and hope this suggested approach facilitates selecting the biologic most suitable for each individual with poorly controlled moderate-to-severe asthma.

First Page

266

Last Page

273

DOI

10.1097/MCP.0000000000000861

Volume

28

Issue

3

Publication Date

5-1-2022

PubMed ID

35131991

Link to Full Text

Share

COinS